{"id":734,"date":"2023-10-11T19:30:49","date_gmt":"2023-10-12T02:30:49","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=734"},"modified":"2024-03-21T21:40:54","modified_gmt":"2024-03-22T04:40:54","slug":"remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/","title":{"rendered":"\u4e34\u5e8a\u8bd5\u9a8c\u53d6\u5f97\u663e\u8457\u8fdb\u5c55\uff1aCBT-009\u548cCBT-004"},"content":{"rendered":"<p id=\"ember1207\" class=\"ember-view reader-content-blocks__paragraph\"><strong>Cloudbreak Pharma\uff08\u62e8\u5eb7\u89c6\u4e91\uff09\u6b23\u7136\u5ba3\u5e03\u00a0<\/strong><\/p>\n<ol>\n<li>CBT-009\u662f\u6211\u4eec\u7528\u4e8e\u6cbb\u7597\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u963f\u6258\u54c1\u65b0\u578b\u773c\u79d1\u5236\u5242\uff0c\u5df2\u4e0eFDA\u8fbe\u6210\u534f\u8bae\uff0c\u5c06\u5728\u7f8e\u56fd\u8fdb\u51653\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/li>\n<li>\u6211\u4eec\u5df2\u5411FDA\u63d0\u4ea4\u4e86\u5728\u7f8e\u56fd\u8fdb\u884c2\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7533\u8bf7\uff0c\u4ee5\u6d4b\u8bd5\u7528\u4e8e\u6cbb\u7597\u8840\u7ba1\u5316\u5c0f\u53f6\u7684\u9996\u521b\u5019\u9009\u836f\u7269CBT-004\u3002<\/li>\n<\/ol>\n<h2 id=\"ember1212\" class=\"ember-view\">CBT-009\u5df2\u4e0eFDA\u8fbe\u6210\u534f\u8bae\uff0c\u5728\u7f8e\u56fd\u8fdb\u51653\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/h2>\n<p id=\"ember1213\" class=\"ember-view reader-content-blocks__paragraph\">\u62e8\u5eb7\u89c6\u4e91\u7684\u6838\u5fc3\u4ea7\u54c1\u4e4b\u4e00CBT-009\u6ef4\u773c\u6db2\u5df2\u4e8e2023\u5e749\u670821\u65e5\u83b7\u5f97\u7f8e\u56fd\u836f\u76d1\u5c40\u7684\u8bb8\u53ef\uff0c \u5c06\u5728\n\u7f8e\u56fd\u7387\u5148\u8fdb\u884c\u4e34\u5e8a3\u671f\u7684\u7814\u7a76\u3002<\/p>\n<p id=\"ember1214\" class=\"ember-view reader-content-blocks__paragraph\">\u963f\u6258\u54c1\u662f\u4e2d\u56fd\u56fd\u5bb6\u536b\u751f\u5065\u5eb7\u59d4\u53d1\u5e03\u7684\u300a \u513f\u7ae5\u9752\u5c11\u5e74\u8fd1\u89c6\u9632\u63a7\u9002\u5b9c\u6280\u672f\u6307\u5357\u300b \u4e2d\u63a8\u8350\u7684\u6cbb\u7597\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u836f\u7269\u3002 \u76ee\u524d\uff0c \u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u662f\u552f\u4e00\u88ab\u8bc1\u660e\u80fd\u6301\u7eed\u6709\u6548\u51cf\u7f13\u8fd1\u89c6\u8fdb\u5c55\u7684\u6297\u80c6\u78b1\u836f\u7269\u6cbb\u7597\u9009\u62e9\u3002 \u7136\u800c\uff0c \u7531\u4e8e\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u5728\u6c34\u6027\u5236\u5242\u4e2d\u4e0d\u7a33\u5b9a\uff0c \u4fdd\u8d28\u671f\u6709\u9650\uff0c \u5bfc\u81f4\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u672a\u80fd\u88ab\u66f4\u5e7f\u6cdb\u7684\u8ba4\u53ef\u4e3a\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u6cbb\u7597\u65b9\u5f0f\u3002 \u56e0\u800c\uff0c \u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u7684\u4e0d\u7a33\u5b9a\u6027\u957f\u671f\u4ee5\u6765\u4e00\u76f4\u662f\u5546\u4e1a\u5316\u7684\u6280\u672f\u969c\u788d\u3002<\/p>\n<p id=\"ember1215\" class=\"ember-view reader-content-blocks__paragraph\">\u963f\u6258\u54c1\u662f\u4e2d\u56fd\u56fd\u5bb6\u536b\u751f\u5065\u5eb7\u59d4\u53d1\u5e03\u7684\u300a\u513f\u7ae5\u9752\u5c11\u5e74\u8fd1\u89c6\u9632\u63a7\u9002\u5b9c\u6280\u672f\u6307\u5357\u300b\u4e2d\u63a8\u8350\u7684\u6cbb\u7597\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u836f\u7269\u3002\u76ee\u524d\uff0c\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u662f\u552f\u4e00\u88ab\u8bc1\u660e\u80fd\u6301\u7eed\u6709\u6548\u51cf\u7f13\u8fd1\u89c6\u8fdb\u5c55\u7684\u6297\u80c6\u78b1\u836f\u7269\u6cbb\u7597\u9009\u62e9\u3002\u7136\u800c\uff0c\u7531\u4e8e\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u5728\u6c34\u6027\u5236\u5242\u4e2d\u4e0d\u7a33\u5b9a\uff0c\u4fdd\u8d28\u671f\u6709\u9650\uff0c\u5bfc\u81f4\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u672a\u80fd\u88ab\u66f4\u5e7f\u6cdb\u7684\u8ba4\u53ef\u4e3a\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u6cbb\u7597\u65b9\u5f0f\u3002\u56e0\u800c\uff0c\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u7684\u4e0d\u7a33\u5b9a\u6027\u957f\u671f\u4ee5\u6765\u4e00\u76f4\u662f\u5546\u4e1a\u5316\u7684\u6280\u672f\u969c\u788d\u3002<\/p>\n<p id=\"ember1216\" class=\"ember-view reader-content-blocks__paragraph\">\u62e8\u5eb7\u89c6\u4e91\u5728\u56fd\u9645\u9996\u521b\u65b0\u578b\u975e\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u5242CBT-009\uff0c \u4e0e\u73b0\u6709\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u76f8\u6bd4\uff0c \u5236\u5242\u7a33\u5b9a\u6027\u5927\u5e45\u5ea6\u63d0\u9ad8\uff0c \u53ef\u4ee5\u663e\u8457\u51cf\u5c11\u963f\u6258\u54c1\u7684\u964d\u89e3\uff0c \u4ece\u800c\u51cf\u5c11\u6742\u8d28\u7684\u4ea7\u751f\uff0c \u4f7f\u5f97CBT-009\u5728\u5ba4\u6e29\u751a\u81f3\u9ad8\u6e29\u4e0b\u53ef\u4ee5\u957f\u671f\u4fdd\u5b58\u3002 CBT-009\u6ef4\u773c\u6db2\u672c\u8eab\u5177\u6709\u9632\u6b62\u7ec6\u83cc\u751f\u957f\u7684\u80fd\u529b\uff0c \u56e0\u6b64\u4e0d\u9700\u8981\u989d\u5916\u6dfb\u52a0\u9632\u8150\u5242\u6216\u8fdb\u884c\u7279\u6b8a\u5355\u5242\u91cf\u5305\u88c5\u3002 \u975e\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u6db2CBT-009\u6240\u9700\u4f7f\u7528\u7684\u5242\u91cf\u6bd4\u73b0\u6709\u6c34\u6027\u6ef4\u773c\u6db2\u4f4e\uff0c \u53ef\u4ee5\u5747\u5300\u5206\u5e03\u5728\u6cea\u6db2\u4e0a\u4ece\u800c\u589e\u52a0\u4e86\u963f\u6258\u54c1\u5728\u773c\u8868\u505c\u7559\u65f6\u95f4\u53ca\u63d0\u9ad8\u751f\u7269\u5229\u7528\u5ea6\u3002 \u6b64\u5916\uff0c CBT-009\u6ef4\u773c\u6db2\u5177\u5907\u773c\u90e8\u8212\u9002\u6db2\u7684\u529f\u80fd\uff0c \u60a3\u8005\u4f53\u9a8c\u611f\u4f18\u5f02\uff0c \u5c06\u4f1a\u663e\u8457\u63d0\u9ad8\u9752\u5c11\u5e74\u60a3\u8005\u533b\u4ece\u6027\u3002<\/p>\n<p id=\"ember1217\" class=\"ember-view reader-content-blocks__paragraph\">\u4f5c\u4e3a\u62e8\u5eb7\u89c6\u4e91\u7684\u6838\u5fc3\u4ea7\u54c1\u4e4b\u4e00\uff0c \u65e0\u6c34\uff0c \u65e0\u9632\u8150\u5242\uff0c \u8212\u9002\u7684\u591a\u5242\u91cf\u5305\u88c5CBT-009\u6ef4\u773c\u6db2\u9884\u8ba1\u5c06\u663e\u8457\u63d0\u9ad8\u60a3\u8005\u7684\u8010\u53d7\u6027\u3001 \u5b89\u5168\u6027\u3001 \u533b\u4ece\u6027\u548c\u4ea7\u54c1\u7a33\u5b9a\u6027\u3002 \u5728\u7f8e\u56fd\u83b7\u6279III\u671f\u4e34\u5e8a\u8bb8\u53ef\u662f\u5b9e\u73b0\u8be5\u836f\u7269\u5546\u4e1a\u5316\u7684\u4e00\u4e2a\u91cd\u8981\u91cc\u7a0b\u7891\uff0c \u4e5f\u662f\u516c\u53f8\u7ee7\u6cbb\u7597\u7ffc\u72b6\u80ec\u8089\u65b0\u836fCBT-001\u540e\u7b2c\u4e8c\u4e2a\u81ea\u4e3b\u521b\u65b0\u4ea7\u54c1\u83b7\u6279\u8fdb\u5165\u7f8e\u56fd\u4e34\u5e8a3\u671f\u3002<\/p>\n<h2 id=\"ember1219\" class=\"ember-view\">CBT-004\u5df2\u5411FDA\u63d0\u4ea4\u4e86\u5728\u7f8e\u56fd\u8fdb\u884c2\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7533\u8bf7\u3002<\/h2>\n<p id=\"ember1220\" class=\"ember-view reader-content-blocks__paragraph\">CBT-004\u6ef4\u773c\u6db2\u5df2\u4e8e2023\u5e749\u670829\u65e5\u9012\u4ea4\u7f8e\u56fd\u836f\u76d1\u5c40\uff0c \u7533\u8bf7\u6cbb\u7597\u5145\u8840\u6027\u7ed3\u819c\u9ec4\u6591\u7684\u4e34\u5e8aII\u671f\u7814\u7a76\u3002 CBT-004\u662f\u4e00\u79cd\u5c0f\u5206\u5b50\u591a\u6fc0\u9176\u6291\u5236\u5242\uff0c \u5728\u975e\u4e34\u5e8a\u836f\u6548\u52a8\u7269\u6a21\u578b\u4ee5\u53ca\u52a8\u7269\u6bd2\u7406\u5b9e\u9a8c\u4e2d\u5747\u663e\u793a\u51fa\u826f\u597d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002 \u6839\u636eFrost &amp;Sullivan\u62a5\u544a\uff0c \u76ee\u524d\u5168\u7403\u5c1a\u65e0\u83b7\u6279\u51c6\u7684\u6cbb\u7597\u5145\u8840\u6027\u7ed3\u819c\u9ec4\u6591\u7684\u836f\u7269\u7597\u6cd5\u3002 \u800c\u5728\u5168\u7403\u8303\u56f4\u5185\uff0c2022\u5e74\u7ed3\u819c\u9ec4\u6591\u60a3\u8005\u4eba\u6570\u8fbe\u523011.496\u4ebf\uff0c 2018\u5e74\u81f32022\u5e74\u590d\u5408\u5e74\u589e\u957f\u7387\u4e3a1.2%\u3002 \u9884\u8ba12027\u5e74\u5c06\u8fbe\u523012.171\u4ebf\uff0c 2032\u5e74\u5c06\u8fbe\u523012.838\u4ebf\uff0c2022\u5e74\u52302027\u5e74\u590d\u5408\u5e74\u589e\u957f\u7387\u4e3a1.1% \uff0c 2027\u5e74\u52302032\u5e74\u590d\u5408\u589e\u957f\u7387\u4e3a1.1%\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>We are proud to announce that\u00a0 CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA to enter into Phase 3 clinical trial in the USA. We have submitted our application to FDA for conducting a Phase 2 clinical trial in the United States to test [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":736,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-734","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Remarkable Progress in Clinical Trials: CBT-009 and CBT-004 - Cloudbreak Pharma, Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cloudbreakpharma.com\/zh\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Remarkable Progress in Clinical Trials: CBT-009 and CBT-004 - Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"og:description\" content=\"We are proud to announce that\u00a0 CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA to enter into Phase 3 clinical trial in the USA. We have submitted our application to FDA for conducting a Phase 2 clinical trial in the United States to test [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cloudbreakpharma.com\/zh\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/\" \/>\n<meta property=\"og:site_name\" content=\"Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-12T02:30:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-22T04:40:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1363\" \/>\n\t<meta property=\"og:image:height\" content=\"575\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"James Gilbert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"James Gilbert\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/\"},\"author\":{\"name\":\"James Gilbert\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\"},\"headline\":\"Remarkable Progress in Clinical Trials: CBT-009 and CBT-004\",\"datePublished\":\"2023-10-12T02:30:49+00:00\",\"dateModified\":\"2024-03-22T04:40:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/\"},\"wordCount\":673,\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"articleSection\":[\"News\"],\"inLanguage\":\"zh-CN\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/\",\"name\":\"Remarkable Progress in Clinical Trials: CBT-009 and CBT-004 - Cloudbreak Pharma, Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"datePublished\":\"2023-10-12T02:30:49+00:00\",\"dateModified\":\"2024-03-22T04:40:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/#breadcrumb\"},\"inLanguage\":\"zh-CN\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"width\":1363,\"height\":575},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Remarkable Progress in Clinical Trials: CBT-009 and CBT-004\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"name\":\"Cloudbreak Pharma, Inc.\",\"description\":\"Seeing Life Better Through Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cloudbreakpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-CN\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\",\"name\":\"Cloudbreak Pharma, Inc.\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"width\":824,\"height\":199,\"caption\":\"Cloudbreak Pharma, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\",\"name\":\"James Gilbert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"caption\":\"James Gilbert\"},\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/zh\\\/author\\\/jgdm18gmail-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Remarkable Progress in Clinical Trials: CBT-009 and CBT-004 - Cloudbreak Pharma, Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cloudbreakpharma.com\/zh\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/","og_locale":"zh_CN","og_type":"article","og_title":"Remarkable Progress in Clinical Trials: CBT-009 and CBT-004 - Cloudbreak Pharma, Inc.","og_description":"We are proud to announce that\u00a0 CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA to enter into Phase 3 clinical trial in the USA. We have submitted our application to FDA for conducting a Phase 2 clinical trial in the United States to test [&hellip;]","og_url":"https:\/\/cloudbreakpharma.com\/zh\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/","og_site_name":"Cloudbreak Pharma, Inc.","article_published_time":"2023-10-12T02:30:49+00:00","article_modified_time":"2024-03-22T04:40:54+00:00","og_image":[{"width":1363,"height":575,"url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","type":"image\/jpeg"}],"author":"James Gilbert","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"James Gilbert","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"4 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/#article","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/"},"author":{"name":"James Gilbert","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3"},"headline":"Remarkable Progress in Clinical Trials: CBT-009 and CBT-004","datePublished":"2023-10-12T02:30:49+00:00","dateModified":"2024-03-22T04:40:54+00:00","mainEntityOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/"},"wordCount":673,"publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","articleSection":["News"],"inLanguage":"zh-CN"},{"@type":"WebPage","@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/","url":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/","name":"Remarkable Progress in Clinical Trials: CBT-009 and CBT-004 - Cloudbreak Pharma, Inc.","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/#primaryimage"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","datePublished":"2023-10-12T02:30:49+00:00","dateModified":"2024-03-22T04:40:54+00:00","breadcrumb":{"@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/#breadcrumb"},"inLanguage":"zh-CN","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/"]}]},{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/#primaryimage","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","width":1363,"height":575},{"@type":"BreadcrumbList","@id":"https:\/\/cloudbreakpharma.com\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cloudbreakpharma.com\/"},{"@type":"ListItem","position":2,"name":"Remarkable Progress in Clinical Trials: CBT-009 and CBT-004"}]},{"@type":"WebSite","@id":"https:\/\/cloudbreakpharma.com\/#website","url":"https:\/\/cloudbreakpharma.com\/","name":"Cloudbreak Pharma, Inc.","description":"\u533b\u836f\u4f7f\u6211\u4eec\u80fd\u66f4\u597d\u7684\u89c6\u89c9\u4eab\u53d7\u751f\u6d3b","publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cloudbreakpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-CN"},{"@type":"Organization","@id":"https:\/\/cloudbreakpharma.com\/#organization","name":"Cloudbreak Pharma, Inc.","url":"https:\/\/cloudbreakpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","width":824,"height":199,"caption":"Cloudbreak Pharma, Inc."},"image":{"@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3","name":"James Gilbert","image":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","caption":"James Gilbert"},"url":"https:\/\/cloudbreakpharma.com\/zh\/author\/jgdm18gmail-com\/"}]}},"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/comments?post=734"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/734\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media\/736"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media?parent=734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/categories?post=734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/tags?post=734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}